Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis

Dami Collier, Collins Iwuji, Anne Derache, Tulio de Oliveira, Nonhlanhla Okesola, Alexandra Calmy, Francois Dabis, Deenan Pillay, Ravindra K Gupta, French National Agency for AIDS and Viral Hepatitis Research (ANRS) 12249 Treatment as Prevention (TasP) Study Group, Dami Collier, Collins Iwuji, Anne Derache, Tulio de Oliveira, Nonhlanhla Okesola, Alexandra Calmy, Francois Dabis, Deenan Pillay, Ravindra K Gupta, French National Agency for AIDS and Viral Hepatitis Research (ANRS) 12249 Treatment as Prevention (TasP) Study Group

Abstract

Background: Second-line antiretroviral therapy (ART) based on ritonavir-boosted protease inhibitors (bPIs) represents the only available option after first-line failure for the majority of individuals living with human immunodeficiency virus (HIV) worldwide. Maximizing their effectiveness is imperative.

Methods: This cohort study was nested within the French National Agency for AIDS and Viral Hepatitis Research (ANRS) 12249 Treatment as Prevention (TasP) cluster-randomized trial in rural KwaZulu-Natal, South Africa. We prospectively investigated risk factors for virological failure (VF) of bPI-based ART in the combined study arms. VF was defined by a plasma viral load >1000 copies/mL ≥6 months after initiating bPI-based ART. Cumulative incidence of VF was estimated and competing risk regression was used to derive the subdistribution hazard ratio (SHR) of the associations between VF and patient clinical and demographic factors, taking into account death and loss to follow-up.

Results: One hundred one participants contributed 178.7 person-years of follow-up. Sixty-five percent were female; the median age was 37.4 years. Second-line ART regimens were based on ritonavir-boosted lopinavir, combined with zidovudine or tenofovir plus lamivudine or emtricitabine. The incidence of VF on second-line ART was 12.9 per 100 person-years (n = 23), and prevalence of VF at censoring was 17.8%. Thirteen of these 23 (56.5%) virologic failures resuppressed after a median of 8.0 months (interquartile range, 2.8-16.8 months) in this setting where viral load monitoring was available. Tuberculosis treatment was associated with VF (SHR, 11.50 [95% confidence interval, 3.92-33.74]; P < .001).

Conclusions: Second-line VF was frequent in this setting. Resuppression occurred in more than half of failures, highlighting the value of viral load monitoring of second-line ART. Tuberculosis was associated with VF; therefore, novel approaches to optimize the effectiveness of PI-based ART in high-tuberculosis-burden settings are needed.

Clinical trials registration: NCT01509508.

Keywords: HIV; antiretroviral therapy; protease inhibitor; second line; virological failure.

© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America.

References

    1. Boender TS, Sigaloff KC, McMahon JH, et al. Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low- and middle-income countries: a systematic review and meta-analysis. Clin Infect Dis 2015; 61:1453–61.
    1. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9:409–17.
    1. Hamers RL, Sigaloff KC, Wensing AM, et al. ; PharmAccess African Studies to Evaluate Resistance (PASER) Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis 2012; 54:1660–9.
    1. Manasa J, Lessells RJ, Skingsley A, et al. ; Southern African Treatment and Resistance Network High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa. PLoS One 2013; 8:e72152.
    1. Estill J, Ford N, Salazar-Vizcaya L, et al. The need for second-line antiretroviral therapy in adults in sub-Saharan Africa up to 2030: a mathematical modelling study. Lancet HIV 2016; 3: e132–9.
    1. Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS 2012; 26:929–38.
    1. Fox MP, Ive P, Long L, Maskew M, Sanne I. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53:500–6.
    1. Johnston V, Cohen K, Wiesner L, et al. Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch. J Infect Dis 2014; 209:711–20.
    1. Levison JH, Orrell C, Losina E, Lu Z, Freedberg KA, Wood R. Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa. Antivir Ther 2011; 16:853–61.
    1. Murphy RA, Sunpath H, Castilla C, et al. Second-line antiretroviral therapy: long-term outcomes in South Africa. J Acquir Immune Defic Syndr 2012; 61:158–63.
    1. Schoffelen AF, Wensing AM, Tempelman HA, Geelen SP, Hoepelman AI, Barth RE. Sustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa. PLoS One 2013; 8:e58526.
    1. Sigaloff KC, Hamers RL, Wallis CL, et al. ; PharmAccess African Studies to Evaluate Resistance (PASER) Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in sub-Saharan Africa. J Infect Dis 2012; 205:1739–44.
    1. Paton NI, Kityo C, Hoppe A, et al. ; EARNEST Trial Team Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med 2014; 371:234–47.
    1. Ciaffi L, Koulla-Shiro S, Sawadogo A, et al. ; 2LADY Study Group Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa. AIDS 2015; 29:1473–81.
    1. Amin J, Boyd MA, Kumarasamy N, et al. ; SECOND-LINE Correction: raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection. PLoS One 2015; 10:e0140623.
    1. Hakim JT, Kityo CM, Walker S, et al. Second-line treatment in sub-Saharan Africa: week 144 follow-up of the earnest trial. Top Antiviral Med 2015; 23:232.
    1. El-Khatib Z, Ekstrom AM, Ledwaba J, et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS 2010; 24:1679–87.
    1. Lathouwers E, De Meyer S, Dierynck I, et al. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis. Antivir Ther 2011; 16:99–108.
    1. Gupta A, Nadkarni G, Yang WT, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One 2011; 6:e28691.
    1. Iwuji CC, Orne-Gliemann J, Tanser F, et al. ; ANRS 12249 TasP Study Group Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (treatment as prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial. Trials 2013; 14:230.
    1. National Department of Health. The 2013 National Antenatal Sentinel HIV Prevalence Survey South Africa. Pretoria: National Department of Health, 2015.
    1. Houlihan CF, Bland RM, Mutevedzi PC, et al. Cohort profile: Hlabisa HIV treatment and care programme. Int J Epidemiol 2011; 40:318–26.
    1. Gall A, Ferns B, Morris C, et al. Universal amplification, next-generation sequencing, and assembly of HIV-1 genomes. J Clin Microbiol 2012; 50:3838–44.
    1. Manasa J, Danaviah S, Pillay S, et al. An affordable HIV-1 drug resistance monitoring method for resource limited settings. J Vis Exp 2014. doi:10.3791/51242.
    1. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003; 31:298–303.
    1. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496–509.
    1. Boyd MA, Kumarasamy N, Moore CL, et al. ; SECOND-LINE Study Group Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet 2013; 381:2091–9.
    1. Hoffmann CJ, Charalambous S, Sim J, et al. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis 2009; 49:1928–35.
    1. Gupta RK, Goodall RL, Ranopa M, et al. ; DART Virology Group and Trial Team High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy. Clin Infect Dis 2014; 58:1023–6.
    1. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach: 2010 revision. Geneva, Switzerland: WHO, 2010.
    1. Burger DM, Agarwala S, Child M, Been-Tiktak A, Wang Y, Bertz R. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother 2006; 50:3336–42.
    1. la Porte CJ, Colbers EP, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004; 48:1553–60.
    1. National Department of Health. National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults. South Africa: National Department of Health 2014. . Accessed 1 August 2016.
    1. Murphy RA, Marconi VC, Gandhi RT, Kuritzkes DR, Sunpath H. Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa. PLoS One 2012; 7:e44793.
    1. Nijland HM, L’homme RF, Rongen GA, et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS 2008; 22:931–5.
    1. Sunpath H, Winternheimer P, Cohen S, et al. Double-dose lopinavir-ritonavir in combination with rifampicin-based anti-tuberculosis treatment in South Africa. Int J Tuberc Lung Dis 2014; 18:689–93.
    1. Iwuji C Dray-Spira R Calmy A, . et al. Does a universal test and treat strategy impact ART adherence in rural South Africa? ANRS 12249 TasP cluster-randomized trial. J Int AIDS Soc 2015; 18: 16–7.
    1. TenoRes Study Group. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis 2016; 16: 565–75.
    1. Casadellà M, Noguera-Julian M, Sunpath H, et al. Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing. AIDS 2016; 30:1137–40.
    1. Levison JH, Orrell C, Gallien S, et al. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One 2012; 7:e32144.
    1. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Protease inhibitor resistance is uncommon in HIV-1 subtype C infected patients on failing second-line lopinavir/r-containing antiretroviral therapy in South Africa. AIDS Res Treat 2011; 2011:769627.
    1. Boender TS, Hamers RL, Ondoa P, et al. Protease inhibitor resistance in the first 3 years of second-line antiretroviral therapy for HIV-1 in sub-Saharan Africa. J Infect Dis 2016; 214:873–83.
    1. Fun A, Wensing A, Verheyen J, Nijhuis M. Human immunodeficiency virus Gag and protease: partners in resistance. Retrovirology 2012; 9:63.
    1. Gupta RK, Kohli A, McCormick AL, Towers GJ, Pillay D, Parry CM. Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays. AIDS 2010; 24:1651–5.
    1. Parry CM, Kohli A, Boinett CJ, Towers GJ, McCormick AL, Pillay D. Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1. J Virol 2009; 83:9094–101.
    1. Sutherland KA, Mbisa JL, Ghosn J, et al. Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length gag-protease genes. J Antimicrob Chemother 2014; 69:3340–8.
    1. Sutherland KA, Ghosn J, Gregson J, et al. HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir. J Antimicrob Chemother 2015; 70:243–8.
    1. Rabi SA, Laird GM, Durand CM, et al. Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. J Clin Invest 2013; 123:3848–60.
    1. Lange CM, Hué S, Violari A, et al. Single genome analysis for the detection of linked multiclass drug resistance mutations in HIV-1-infected children after failure of protease inhibitor-based first-line therapy. J Acquir Immune Defic Syndr 2015; 69:138–44.
    1. Giandhari J, Basson AE, Coovadia A, et al. Genetic changes in HIV-1 Gag-protease associated with protease inhibitor-based therapy failure in pediatric patients. AIDS Res Hum Retroviruses 2015; 31:776–82.
    1. Gregson J, Kaleebu P, Marconi VC, et al. Occult drug resistance to thymidine analogues and multidrug resistant HIV-1 following failure of first line tenofovir-based antiretroviral regimens in sub-Saharan Africa: a retrospective multi-centre cohort study. Lancet Infect Dis 2016; doi:10.1016/S1473–3099(16)30469–8.
    1. Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012; 380:1250–8.
    1. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis to ART. Available at: . Accessed 1 August 2016.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir